The integration of artificial intelligence (AI) and machine learning (ML) in the management of chronic obstructive pulmonary disease (COPD) and asthma has rapidly emerged as a transformative approach, facilitating enhanced diagnostics, personalized treatment plans, and improved patient outcomes. This revolution is largely driven by the vast amounts of data generated through medical records, respiratory sound analysis, and imaging technologies, as well as advancements in computational techniques. It is essential to explore how current research leverages AI to address the complexities of these respiratory diseases, focusing on diagnostic accuracy, predictive modeling, and the prospect of personalized medicine.

Early studies have demonstrated the efficacy of machine learning algorithms in diagnosing asthma and COPD with substantial specificity and sensitivity. For instance, Spathis and Vlamos reported that the Random Forest classifier achieved a diagnostic precision of 80.3% for asthma, identifying key factors such as maximum expiratory flow, smoking status, age, and wheezing as significant attributes influencing diagnosis (Spathis & Vlamos, 2017). The findings were supported by other studies highlighting the effectiveness of Random Forest in accurately detecting asthma compared to conventional methods (Spathis & Vlamos, 2017). Furthermore, advancements in deep learning have generated improved diagnostic frameworks, enhancing traditional ML approaches by employing models such as Long Short-Term Memory (LSTM) networks, which can analyze temporal data patterns to predict disease outcomes more effectively (Yu et al., 2021).

The utilization of electronic health records (EHRs) to train machine learning models presents a significant opportunity for predicting the recurrence of respiratory pathologies, enriching current clinical practices with data-driven insights (Rodríguez et al., 2021). Chronic lower respiratory diseases often exhibit heterogeneous characteristics necessitating precision in management. Unsupervised machine learning techniques have successfully identified latent clusters among patients with asthma and COPD, enabling clinicians to implement targeted interventions based on identifiable phenotypes (Cui et al., 2020). This tailoring of treatment, complemented by continuous data collection through devices like wearables and the Internet of Medical Things (IoMT), allows for dynamic adjustments in therapeutic strategies as patient conditions evolve (Santana-Mancilla et al., 2023).

Moreover, digital health strategies have shown promise in improving asthma monitoring through AI-enhanced platforms that analyze patient data for more accurate control assessments (Novembre et al., 2022). By systematically tracking symptoms and medication adherence, these technologies empower both patients and healthcare providers to engage in more informed dialogues about disease management, thereby facilitating proactive interventions. This is especially relevant in low- and middle-income countries (LMICs), where access to updated management strategies for asthma is often limited (Ozoh et al., 2022). By employing AI, healthcare systems can adapt to local needs, improving the overall management framework for respiratory diseases.

The intersection of AI and medical imaging represents another frontier for enhancing COPD and asthma management. Deep neural networks (DNNs) have been effectively applied to analyze chest radiographs and other imaging data, facilitating the identification of pathological conditions that might otherwise go unnoticed (Gonem et al., 2020). Studies illustrate that such models can achieve diagnostic capabilities exceeding traditional image analysis methods, providing a basis for timely and accurate assessments of patients’ respiratory health (Bansal, 2021).

Additionally, acoustic signal analysis has emerged as a novel avenue for classifying respiratory disorders, harnessing ML algorithms to analyze respiratory sounds such as wheezing, coughing, and other abnormal patterns. Techniques like convolutional neural networks (CNNs) have demonstrated high effectiveness in differentiating between various lung conditions based on audio inputs, presenting opportunities for non-invasive diagnostics (Sfayyih et al., 2023;, Srivastava et al., 2021). The ability to detect respiratory anomalies through sound can significantly enhance early intervention efforts, ultimately reducing morbidity associated with respiratory diseases.

Another pivotal aspect revolves around the predictive capabilities of AI in assessing risks associated with respiratory diseases, particularly in older adults. Machine learning models validated on respiratory frequency data have illustrated profound potential for forecasting respiratory events, which is crucial for preemptive healthcare measures (Santana-Mancilla et al., 2023). These predictive analytics enable healthcare providers to develop tailored care pathways, ensuring that at-risk populations receive timely interventions personalized to their specific health profiles.

The development and implementation of tailored predictive models for respiratory diseases necessitate rigorous training algorithms capable of managing complex datasets. Advances in methods such as Support Vector Machines (SVM) and other supervised learning frameworks have proven instrumental in constructing reliable prediction systems that categorize patients based on risk assessment models (Uddin et al., 2019). Notably, the implementation of these systems has been correlated with enhanced clinical decision-making, ensuring that patients with severe cases of COPD or asthma can receive immediate and appropriate care (Li et al., 2022).

Each of these advancements underscores the critical importance of a multidisciplinary approach in integrating AI into respiratory care. Collaborative efforts between computer scientists, healthcare professionals, and regulatory bodies are crucial in navigating the ethical and practical considerations inherent in utilizing AI in medicine. As the landscape of COPD and asthma management continues to evolve, ongoing research efforts are pivotal in validating the effectiveness of these technologies while simultaneously addressing barriers to their adoption in clinical settings.

The future of COPD and asthma management lies in effectively harnessing the vast potential of AI to enhance diagnostic accuracy and treatment efficacy while transforming patient engagement through personalized care pathways powered by real-time data analytics. AI-driven interventions have the power to streamline healthcare resources while improving disease management outcomes, thereby revolutionizing the way respiratory diseases are addressed across diverse healthcare settings.

In conclusion, the integration of AI and machine learning into the management of COPD and asthma represents a key milestone in the evolution of respiratory medicine. While challenges remain in terms of implementation, validation, and ethical considerations, the promising advancements documented in the literature indicate that with continued research and collaborative efforts, significant improvements in respiratory health outcomes can be achieved.